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Systemic hypertension, one of the most eommoncx3mphtions 
oimming in patients after heart tfanspbtatkq has a reported 
ioeidenoe rate of HO% (l-4). It is often diffhlt to treal, and 
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being treated with cyclosporine and had a supine blood 
pressure ?140/90 mm Hg on ~3 separate days despite a 
restricted sodium diet. All patients gave written informed 
consent. Patients were excluded if they had known sensitivity to 
lisinopril, diltiazem or acy angiotensin-converting enzyme- 
inhibiting drug aozelerared or malignant hypertension; serum 
creatinme >Z5 mg/dl; or second- or third-degree atrioventric- 
ular (AV) block unless a normally functioning pacemaker was 
present. 
Protoe& Patients were randomized to receive either dilti- 
axem or lisinopril. Treatment with sustained-release diltiazcm 
was started at 90 mg, twice daily; the dose could be increased 
weekly up to a maximal daily dose of 360 mg. Given diltiaxem’s 
effect of increasing cyclosporine levels, cyclosporine doses 
were adjusted accordingly. Treatment with lisinopril was 
started at a dose of 10 mg daily; the dose could be increased 
weekly to a maximal dose of 40 mg daily. All patients were seen 
every 1 to 2 weeks during the titration phase. Once blood 
pressure control or maximal aose was attained, patients were 
foIlwed up for 2 months and seen at least monthly. Weight 
and blood pressure measurements (average of two successive 
blood pressure readings), a brief examination and review of 
side effects and concomitant medications were performed at 
each visit, and any intercurrent rejection episodes were re- 
corded. Laboratory studies included a complete blood count, 
routine blood chemistry determinations, and cyclosporine 
level. Patients receiving diltiazem had an electrocardiogram 
(ECG) performed if the dose had been increased. Diuretic 
drugs were used on an as-needed basis only for treatment oi 
edema as deemed appropriate by the investigator. 
Patients were withdrawn from the study for serious events 
such as rejection with hemodynamic compromise, severe in- 
fection, renal faihnq hyperkalemia, angioedema or heart 
blodc. 
Choke of dmgs. The investigatars chase to examine the 
effects of two diierent classes of vasodilators-calcium- 
channel antagonists and angiotenskonverting enzyme inh~&- 
itors-because of the collective clinical experience with these 
two classes of drug. Diltiazem was chosen as the calcium 
channel antagonist because of its favorable effect on t-@os~ 
rhe IeveL L&mpril was chosen as the angioteusin-converting 
enzyme inhibiting drug because it is effective with once-daily 
m 
SeaMcal amdysk. All data were entered and analyzed at 
the CTRD Data Coordination and Analysii Center at the 
Unker&yofAiabamaatBii.Tbesuecessafdilti- 
azemandkiqrilwerecomparedbyachi-squaretestfor 
com@ngpqMntionsofsua!essforthetwodNgs.Dataare 
repmtedasmeanv&e~1SEM.Patientskreco&kred 
reDpondersiftheymaintainedasupinediasto&bloodpressure 
40mmHgand mnmqmdersiftheyhadasupinediastk 
hla3dpNasnre~mmHgwithmaximaldaseafthestudy 
dNg.fzhlgesin~levelswerecx#aparedwithin 
rn~~~~~~~~~~~~ 
dvarhmz. 
Table 1. Baseline Data 
Total Group Diltiazem Lkiwpril 
(n = 116) (n = 55) (n = 61) 
4s w 52+15 55 5 1.3 53 + 1.2 
Male (%) 80 80 80 
Months after transplantation 3.4 + 0.24 3.3 t 0.36 3.4 2 0.33 
Creatiniae (mgidl) I.40 + 0.03 1.46 + PO5 1.46 ? o.Od 
Initial systolic BP (mm Hg) 155 + 1.0 155 2 1.4 155 5 I5 
Initial diastolic BP (mm Hg) 102 t 0.6 102 2 1.0 101 z 0.8 
Daily prednisone (m&g 0.12 -c 0.01 0.12 2 0.02 0.11 t 0.01 
body neight) 
Daily qclosporine (mgkg 
body weight) 
2.8 + 0.11 2.9 t 0.19 2.12 0.12 
Tlwe are no significant dilieerenoes between gmaps. Ualess othervise 
indicated, data are presented as mean value + I SEM. BP = blood preswe. 
Results 
Baseline data Of 116 randomized patients, 94 (81%) 
completed the protocol and 22 (19%) were withdrawn from 
the study because of adverse events. Table 1 shows baseline 
data for the initial 116 patients and the two randomized 
groups. There was no significant difference among groups in 
age, gender, time after rransplantation, serum creatinme level, 
initial blood pressure or daily doses of cyclosporine and 
prednisone at study entry. 
Drug efficacy. Of the 55 patients receiving diltiazm, 21 
(38%) were responders (95% confidence limits [CL] 26%, 
52%), 23 (42%) were nonresponders (95% CL 29%, 56%) and 
11(2M& 95% CL ll%, 33%) were withdrawn from the study 
because of adverse events Of the 61 patients receiving lisino- 
pril, 28 (46%) were responders (95% CL 33%, 59%), 22 (36%) 
were nonresponders (95% CL 24%, 49%) and 11(18%; 95% 
CL lO%, 30%) were withdrawn from the study because of 
adverse events. There were no differences between the patient 
groups receiving diltiazem or lisinopril in terms of percent 
responders, nonresponders and patients withdrawn from the 
study. Table 2 compares results among responders, non- 
responders and patients withdrawn from tbe study in each drug 
treatment group. 
There were no differences among the responklers, non- 
responders and patients withdrawn from the stu&~ with re- 
spect to age, gender, time after transplantation, initial cyclo- 
sporine and prednkone doses, final, cyclosporine dose. initial 
creatinine level or initia! blood pressure measurements. Re- 
sponders in both treatment groups had a significant Uerencc 
insy&icanddiastolicbloodpressurr.Tbemag&&of 
dmngeinthsystoliianddiibloodpressmemeasure- 
merits (Fii 1) did not differ between the two treatmeot groups. 
Systolic pressure decreased from 157 + 2.3 to 130 2 
20 mm Hg in the diltiazm-treated nqonderx (p < O.OIHU) 
and from 153 ” 2.1 to 127 2 2.7 mm Hg in the lkkpril- 
treatedresp&em(p<o.o1x)1)withan~~doseof 
18t22mg+Dipr@suredecreasedfikMl100~0.9to 
852 1.6mmHgintheditt&m-trearednqondetP@< 
O.oool) and from la0 + 1.0 to w ‘- 2.0 mm ,FIg in the 
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Tabk 2. Resuits in Responders, Nonrespnders and Patients Withdrawn From the Study 
Drltiazem Lisinopil 
(n ,R21) 
NR 
(It = 23) (0 51, 
R NR W 
h = 28) (a = 22) In = 11) 
AgeQ 
Male VW 
b4ontbs aher 1ransplamati0n 
CLclosporine hgntg body +W) 
Initial 
Final 
Predniwne (mgkg body weight) 
t&al 
cre.?tinine (nlgl) 
Initial 
Fii 
Systolic BP (mm&Q) 
lniil 
Fii 
Diastolk BP (mm&) 
Initial 
Fillal 
he dox (d&Y) 
52 2 1.5 
81 
3.6 + 0.6 
3.1 -r 0.35 
2.6 I 0.62 
0.11 2 0.01 
1.36 5 0.07 
1.54 2 0.09’ 
157 i 2.3 
130 + 2.0$ 
100 z 0.9 
85 z 1.6.$ 
280% 18 
5oc2.1 
63 
3.4 t 05 
2.8 2 0.27 
2.2 2 034 
0.15 2 0.05 
1.62 2 0.08 
1.59 k OM 
153 5 2.0 
150 t 4.1 
52 = 29 
73 
2.7 2 0.9 
3.0 2 036 
2.8 2 0.66 
51 + 2.1 
79 
3.1 2 0.6 
55 T 1.4 52 I 1.9 
91 64 
2.5 2 0.2 4.4 z 0.9 
2.6 i 0.22 2.8 2 0.25 
3.2 t n53 3.0 = 0.09 
2.7 zo.17 
2.1 z 0.3? 
0.11 + 0.01 
I.35 f 0.11 
I.68 i 0.34 
156 f 3.u 
13t t 8.0 
0 1 I r IJ.01 
1.43 z 0.06 
L55roo8 
0.1 f 0.01 
I.40 z IJ.ch 
1 .a = 0.0% 
0.11 f 0.03 
I.65 t 0.12 
LW=O.l9 
153 I 1.1 IW f 2.7 153 z 3.6 
127 2 2.71 M9r23 134 T_ 7.0 
104 f 1.7 
104223 
320215 
1w f 1.0 103 I 15 I02 L 2.1 
84rZ.l@ 101 + I.9 92252 
18 f 2.2 32 3 2.3 lJr2.8 
“p = O.&Z, tp = O.(k?& $p = ~O.ooOl, initial versus tinal treatment. Unless otherwise indicated. data are prewnted as mean vatw 2 SEM. BP = Mood pressure: 
NR = nonresponders; R = rqmders; W = withdrawn. 
hsiiopril-treated responders (p < 0.0001). There was no 
change in either systolic or diastolic pressure in diltiazem- 
treated nonrc~~~~ : f cc il‘k ‘1 There was a modest but not 
significant decrease III systolic pressure (160 to 149 turn Hg) in 
lkinopril-treated nonresponders. There was no difference in 
the time to attain blood pressure control in responders in 
either treatment group (diftiazcm 3.6 months, hsiioptil 3.7 
months). Patients in the nonresponder group participated for 
an average of 4.2 months (dihiazem 3.4 months, lkiiril5.1 
months) as dose titration continued to the maximal dose of the 
respective drug. 
Serum creatiuiue. There was a significant increase in se- 
rum creatinine in the diltiazem-treated responders (1.36 to 
1.54 mgdl, p = 0.02) and the hsinop&t~ted nonresponders 
(1.40 to 1.68 mgdl, p = 0.002). 
Cydosporiw lmk. Exh institution used the qclosporine 
assay available through its respective laboratory. Cyclosporine 
trough levels were therefore analyzed by grouping patients in 
whomthc.sameamaywasused.Table3shomtheavaila& 
data including the type of assay used, as well as baseline and 
posttreatment q&sporine levels in both treatment groups. 
Except for seven diftiazem-treated pat&ruts in whom the 
Blood pressure (BP) results in 
or lkinopril therapy. 
rg 
to 
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0 initial BP. diltiazem 
WIimn rmliazem LkiNtQM 
n-23 w P w-23 n-22 
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Final BP, diltiazem 
! Initial BP lisinopril 
q Final EP,~isinqxi: 
Fii 2. Blood pressure (BP) results in nonresponders to 
diltiazem or lisiiopril therapy. 
nonspecific radioimmtmoassay was useu, the cyclosporine level 
was lower at the end of the study than at baseline in both 
groups. This decrease may reflect the clinical practice of 
dexxeahg the target cyclospmine level over time. 
Eteetroeanliograp$ . A baseline ECG was performed in 
all patients Serial ECGs were obtained after initiation of 
therapy or an increase in dose only in the dihiazem-treated 
group. There were no occurrences of second-degree or high 
grade AV block or symptomatic bradycardia in this group. 
Adverse events” 10 the 55 patients treed with diltiazem, 
18 adverse events were reported In this group, the most 
common side effect was edema (tive patients). Eleven patients 
were withdrawu from the study because of adverse events, not 
ah of which were considered drug-related. There were two 
deaths. One patient died from pneumonia; the cause of death 
in the other patient is unknown but is not believed to be related 
to dihiazem. In the 61 patients treated with Iiiinopril, 17 
adverse events were reported. IO this group, the most common 
side effect was hypoteosioo (three patients). Eleven patients 
were withdrawn because of adverse events and there were no 
deaths. As with the diltiazem group, not all adverse events 
‘*~erc considered drug-related. Table 4 lists the adverse events 
in both groups and indicates which events were considered 
drug-related and which resulted in withdrawal from the study. 
AII drug-related events resolved with discontinuation of the 
drug. 
Tahk 3. QclosPorine Trough Levels 
F%ueahwllr Posttreatment 
24oe3a 
340269 
03 
I1 
6 
5 
10 
180~89 0 10 
0.4 
-90 2 31t 0.05 
70268 0.3 
0.14 
60~27 0.04 
30226 03 
0.4 
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TahIc 4. Adverse Events 
Diltiazem l.swpd 
Adverse Event (n = 55) (a = 61) 
Hypotetion 2 (1) PI 5 (4) 121 
Edema 5 (5) PI 
Patient* 1 @)I11 3 (3) PI 
Imeaseinsemmcreatinine l(l) PI 2 (2) VI 
Headache tCt)ltl l(1) 111 
Hyperkaleti 212)111 
TremOr 2 0 IO1 
Hrperteosion 2(QM 
lhth 2 (0) 121 
Aoergic reaction l(1) PI 
Elevated a&line pbosphacax l(O) PI 
aush l(1) it1 
Ageosia l(1) 111 
Frachxe femoral reds l(O) Ill 
Nmnhen itt pareatbexs ii&ale the number of patients wbme adverse 
event was drug related; the namhers in brackets indicme the number ofpatieots 
whowwewithdrawnfmmtheshldyhecauseoftheadverseevem. 
Discussion 
Compared with essential hyperteosion, hypertension after 
heart transplaotation is charactd by features such as onset 
within days to weeks of transplantation, lack of normal noc- 
turnal decrease in bIood pressure and the elect of denervation 
on the left ventrictdar response to high systemic vascular 
resistant (56). Potential etiologic factors are multiple and 
inchtde treatment with q&spot&, obesity, sympathetic neu- 
ral activation, eIkts of the renin-an-aldosusldosterooe sys- 
tem, v&me expansion, renal dy&nckn and, possibly, a 
cy&sporine-induced alteration of vascular response to endo- 
theIin (7-12). 
lJft.blsatJldyThissttulyhasshowBlhat 
lofhypetiensionduringthelstyearafter 
hearttram@antationcanbeachievedtymonotherapywith 
long-acting diItiazem in 38% of patients and with IkinopriI in 
46%ofpatients.Therewasnodifferencciothe~ofthe 
twodrugsorinthenumberofpatientsineachgnntpwith- 
drawn from the study because of adverse events. The treatment 
sampIesimsweresn&iemlylargetohaveapowerof8096to 
detecta~ereoceinsuocessrateofl~attheO.lOlevelof 
T . . t?nammeshowedastatisticaltybtltnotdinicslly 
significaot~iDtwogroupi:dii~-Mresponcc 
elsandIitkpamtednoorespondershug-related* 
everltswereolioorand~with~~ofthe 
tespe&eQug~~notIilferencesinWicharac- 
te~betweenrespondenandm#uespon delxfromwhi&to 
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incidence of hypertension in patients who continue to receive 
maintenance steroid therapy than in those who are ,m a 
steroid&x protocol. Another study (16) evaluated the effects 
of a low versus a high sodium diet in 12 patients after heart 
transplantation. Systolic blood pressure was signi6cantly lower 
in the low sodium group, and the increase in both plasma renin 
activity and plasma atrial natriuretic peptide was blunted in 
these patients. In a retrospective study of 50 patients with a 
thoracic organ transplant (17), 45 of which were heart trans- 
plants, patients received either praaosin or nifedipine and had 
satisfactory bIood pressure controI with either drug. Creatinine 
clearance was better preserved in the nifedipine-treated .?oup, 
indicating a possible nephroprotective effect of this calcium 
channel bIocking agent. in a smah prospectbe study of nine 
patients (18) treatment with enalapril and diuretic agents was 
started shortly after transpIantation for treatment of hyperten- 
sion. With an average dose of 11 mg of eoalapril daily, in 
combination with an average dose of 62 mg of furosemide 
daiIy, adequate blood pressure control was obtained, and the 
serum creatinirte Ievel did not r&e during the follow-up petkd 
ofupto2years. 
The effects of omega-3 fatty acids on control of posnmm- 
pIant~rtensionwasakoexaminedinarandomtmdtrialof 
2OhearttmnspIantmcipients(19).Fbesuhsinthistrialshowed 
a15%decreaseinmeanarteriaIpressureanda32%reduction 
in systemic vasadat ret&am-e. 
In d l-month doubk-bliud crossovct trial of amludipim or 
Ikinopril in the treatment of hypertension in q&sporine- 
treated patients with a renal tmnsplant @I), amlodipine was 
found to be more effective than Iiiinopril in controlling 
hypertension. It was also assocmted with a consistent in- 
crease in glomerular filtration rate and effective renal 
plasma flow. 
thisstudyisthefirstcdabw 
ra multicentertrialofthetreat- 
mentofhypertet&minpatientsafterheart~ 
andhasalargera~ofpakntstItanprevhn+qorted 
triaI&certainlimMmnsshouIdhe~l)~trialwas 
desiionIytodetefmineshort-termefScacyarIdsaretyof 
dittiYemnrfisiwprilhlthe-tofhypertcnsioaaluriag 
the1stye1ratkliearttraosphntation.)lltetriaIdidnot 
examinedteeSectsofeitheradiureticafgntustxicmaoas 
neededb&sforedemaorascumdan~dqgat 
bloodpremureaontid3)PomibIempmlaeof~in 
eadllreatmeatgroltpanddNgelf~onthc8eseque~c 
notstndied4)cLebsporiacasseyswere~ineach 
irwtituticnlwithouttbebenefitofacentralI$noraborlr.Unifor- 
mityincrclosporioeassaysvmddhsveimpmKdtlse~ 
OfCbllgESilItkr)rlospaineLeveh~aitbngord 
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different pharmacologic effects of each drug-namely, vaso- 
d&&on by calcium channel antagonism or inhibition of the 
renin-angmteusm-aldosterone system by angiotensinconverting 
enzyme inhibition-our results suggest that the underlying 
pathophysiologic mechanisms can be altered by different ap- 
proaches to therapy. In view of the long-term sequelae of 
posttransplant hypertension, further study of the underlying 
mechanisms, efficacy of selected drugs and the long-term 
effects of hypertension in these patients is needed. 
Appendix 
Cardiac Tmnsplant Research Database 
Group Partic@nts * 
Uev&td Clmic Robert Hobbs MD,? Karen B. James, MD, 
Corinne Bott-Siienuaa, MD, Mark Jamsz, RN, David Pekgrin, RN, 
PA tiakmaan Uukrstt Hespitsl: Susan C. Brozena, MD,? Jane 
Fie MD, Arnold K. Gash, MD, Carol Twomey, RN, MSN, 
Donua Choiwwsgi RN, BSN, Patricia Stutmau, RN, MSN. Hershey 
MedkatCeutcxBanyCteuucu,MD,t(~addrePs:St.Fraucis 
Hospital, Peoria, IL), David Pawbrsh, MD, Dwight Davis, MD, Cindy 
Helm, PA. Lq&i UatverstQ ef cbiepgo: Mary) R. Johusoa, MD,t 
(Preserr~ &resr: Rush-Presbyterian-St Luke’s Medical Center, Chi- 
cago, IL), Maria Rosa Costaazo, MD, G. Martin Mullen, MD, Atain 
Herous, MD, Walter ffio, MD, James J. Glazier, MD, Patricia 
schl~r, RN, Carrie Giiq RN. MedkaI CeRPg d VII: 
Rebecca Otti& MD,t (Preamf tafdmx Northwestern University, 
~~)~~~. ~Gldasne4RN,MaryEJizabcth . . lmatmmm H&or 0. Veutura, MD,? 
Frank Saxart, MD, Dwight Staptetoe, MD, Debi Dumas, RN, Mary 
Lou Vau Tey&eu, RN. Sahtt Louts Um ktie Miller, MD,? 
Steven Jeuukou, MD, Naacy No&t, RN. Tem#e Unkrsity Host& 
tok susau c. &ozel& MD,t (pkswt oddrex HahnenulM Univetsity 
H~~PA~~L~~,~a~n~MD, 
Carol Tmmey, RN, MSN, Dotma c%cjm&& RN, BSN, Patricia 
stuhnan, RN, MSN. lktkdy of Robert 
Bow& Id&t James F. Rirldia, MD, David McGblin, MD, Gnmii 
White-W- RN, Peggy Blond, RN, Jeuay Bretaud, RN, &&xi- 
&II: David NafteL PhD Stnt&xl coo&nakx ApryJ Crosswy. Uak 
versIty cd PterMa: Roger Mii MD.? Marian Limacber, MD, Chuck 
Md3m RN, Susan Selmim RN, Kaye Worley, RN. Uatwn&ty d 
Tesas, SW? Maria Teresa Dtivari,t (Preseti uc’dmx University of 
kbrasba, Omaha, Nbraska), Nancy Johnsott, RN, Patricta Raiser, 
RN, Cathy Lelsinger, RN. 
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